Black Diamond Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $37,483 | $(53,691) |
| Adjustment to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,216 | 8,991 |
| Depreciation expense | 259 | 258 |
| (Accretion) amortization on investments | (1,130) | (3,057) |
| Gain on sale of investments | (3) | — |
| Noncash rent expense | 2,340 | 2,213 |
| (Gain) Loss on sale of equipment | (24) | (86) |
| Changes in current assets and liabilities: | ||
| Prepaid expenses and other current assets | (98) | (222) |
| Other non-current assets | 132 | (293) |
| Accounts payable | (3,032) | (353) |
| Accrued expenses and other current liabilities | (1,996) | 1,507 |
| Non-current operating lease liabilities | (2,746) | (2,515) |
| Net cash provided by (used in) operating activities | 36,401 | (47,248) |
| Cash flows from investing activities: | ||
| Proceeds from sale of equipment | 24 | 86 |
| Proceeds from sales and maturities of investments | 86,083 | 109,000 |
| Purchases of investments | (128,123) | (119,887) |
| Net cash provided by (used in) investing activities | (42,016) | (10,801) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options and ESPP, net of restricted stock surrendered for taxes | 50 | 762 |
| Proceeds from issuance of common stock, net of issuance costs | — | 24,494 |
| Net cash provided by financing activities | 50 | 25,256 |
| Net (decrease) increase in cash and cash equivalents | (5,565) | (32,793) |
| Cash, cash equivalents and restricted cash, beginning of period | 37,256 | 57,044 |
| Cash, cash equivalents and restricted cash, end of period | $31,691 | $24,251 |
| Cash and cash equivalents, end of period | $30,864 | $23,425 |
| Restricted cash, end of period | 827 | 826 |
| Cash, cash equivalents and restricted cash, end of period | $31,691 | $24,251 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.